Hologic (HOLX)
(Delayed Data from NSDQ)
$80.24 USD
+1.02 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.24 USD
+1.02 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is currently focusing on improving clinical quality.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.
HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.
Hologic (HOLX) Receives Global Nods for Omni Hysteroscope
by Zacks Equity Research
Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.
Here's Why Momentum Investors Will Love Hologic (HOLX)
by Zacks Equity Research
Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.
Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.51%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.
Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic Stock Rides on Impressive Preliminary Q1 Result
by Zacks Equity Research
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
Hologic's (HOLX) New Offering to Revitalize Cynosure Division
by Zacks Equity Research
The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
by Zacks Equity Research
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
Why Is Hologic (HOLX) Up 1.9% Since Last Earnings Report?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.
Hologic (HOLX) Misses Q4 Earnings Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of -1.69% and 1.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Women Health a Prime Concern Worldwide: 3 Stocks in Focus
by Zacks Equity Research
Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.
Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm
by Zacks Equity Research
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Hologic (HOLX) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic Launches Fluent Fluid Management System, Widens Suite
by Zacks Equity Research
Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.
Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.